Cencora Acquires Oncology Network for $2.4 Billion
The deal signals a major expansion in community oncology management that will affect competition across 21 states.
Updated on Oct. 30, 2026 in Healthcare
Live Poll
Do you support large pharmaceutical companies acquiring independent oncology practices?
Cencora has announced an agreement to acquire American Oncology Network in a deal valued at up to $2.4 billion. The transaction aims to scale Cencora's physician practice management operations in community oncology across the United States.
Why it matters
By acquiring a larger stake in this provider network, Cencora intends to expand its service footprint into 12 additional states. This move signals a broader consolidation trend in specialty care management as national distributors seek deeper integration with physician practices.
The deal includes a base valuation of $2.3 billion plus $100 million in contingent value payments. Cencora will acquire a 75% stake in the network, which currently serves more than 350 providers across 21 states.
The players
Cencora
A pharmaceutical sourcing and distribution company providing drug distribution and practice management services.
American Oncology Network
A physician-led practice management organization serving oncology providers across 21 states.
The details
Cencora will move to acquire a majority interest, while allowing American Oncology Network shareholders to retain up to a 25% ownership stake through an equity rollover. The integration focuses on embedding Cencora’s management infrastructure into the existing provider footprint to drive operational efficiencies. Cencora noted the acquisition is expected to become accretive to its adjusted diluted earnings per share starting in the second year post-closing.
Timeline
2020: Cencora began its initial investment in American Oncology Network.
October 30, 2026: Cencora announced the agreement to acquire the network.
November 4, 2026: Cencora will conduct its fourth-quarter earnings call.
Market Landscape
This acquisition follows the industry-wide pattern of large distributors moving beyond logistics to gain direct control of physician practice management. It represents a significant step in the vertical integration of oncology service delivery within the broader specialty pharmacy sector.
Operators in the specialty care space should monitor how this vertical integration affects regional pricing and service access for community oncology providers. Management should track the regulatory review process as a benchmark for potential future consolidation in their own service sectors.
The takeaway
This acquisition highlights the aggressive push by national distributors to control the physician-facing side of community specialty care. Owners should monitor the regulatory approval timeline for this deal as a potential signal for shifting competitive dynamics in specialty practice management.
What happens next
Cencora will host its fourth-quarter earnings call on November 4, 2026, where it is expected to provide further details on its fiscal 2027 outlook.
Further reading
For more on industry shifts, visit the Healthcare section.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you support large pharmaceutical companies acquiring independent oncology practices?
